Sarepta Therapeutics (SRPT) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8036071004

(NASDAQ:SRPT Stock) Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Web URL: https://www.sarepta.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Sarepta Therapeutics (SRPT) - Stock & Dividends

SRPT Stock Overview

Market Cap in USD 11,908m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1997-06-03

SRPT Stock Ratings

Fundamental -4.44
Dividend -
Growth 5y -1.13
Rel. Performance vs Sector -0.13
Analysts 4.35
Fair Price Total Ret. 121.34
Fair Price DCF -

SRPT Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

SRPT Growth Ratios

Growth 12m 4.59%
Growth Correlation 12m -38%
Growth Correlation 3m 85%
CAGR 5y -1.63%
CAGR / Mean Drawdown -0.05
Sharpe Ratio 12m -0.01
Alpha vs SP500 12m -16.60
Beta vs SP500 5y weekly 0.75
CAPM 7.29%
Average Daily Range 2m 3.57%
Regime Oscillator 83.92
Volatility GJR Garch 1y 58.44%
Price / SMA 50 19.08%
Price / SMA 200 18.43%
Current Volume 806k
Average Volume 20d 943.9k

External Links for SRPT Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of SRPT stocks?
As of February 22, 2024, the stock is trading at USD 132.29 with a total of 805,983 shares traded.
Over the past week, the price has changed by +6.43%, over one month by +9.29%, over three months by +57.34% and over the past year by +8.51%.
Why is SRPT stock down?
Check with which Index or Commodity SRPT has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return SRPT Return S&P 500
1 Month 9.29% 2.85%
3 Months 57.34% 10.14%
12 Months 8.51% 26.48%
What is the forecast for SRPT stock price target?
According to ValueRays Forecast Model, SRPT Sarepta Therapeutics will be worth about 131.3 in February 2025. The stock is currently trading at 132.29. This means that the stock has a potential downside of -0.76%.
Issuer Forecast Upside
Wallstreet Target Price 150.4 13.7%
Analysts Target Price 180.6 36.5%
ValueRay Target Price 131.3 -0.8%